Most Read

This recommendation is for ZTALMY to serve as the adjunctive treatment of epileptic seizures related with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17

VMX-C001 is a modified recombinant human blood clotting factor X that enables patients taking direct oral anticoagulant blood thinners to undergo emergency surgery without the risk of bleeding.

Under the partnership, the biosimilars will be developed and supplied by Alvotech while Advanz Pharma will be responsible for registration and marketing in Europe. Alvotech and Advanz’s agreement

Co-packaged with sulbactam and durlobactam injections, XACDURO is said to be the first pathogen-targeted therapy addressing Acinetobacter, including resistant strains. It is intended for use in patients aged

As per the terms of the exclusive agreement, Genpharm will distribute IMCIVREE to patients in GCC countries, including United Arab Emirates, Saudi Arabia, Kuwait, Oman, Qatar and Bahrain.

The committee voted in support of approval for the vaccine candidate to help prevent the virus in infants through maternal immunisation. According to the committee, the available findings

Kapruvia has been recommenced to treat moderate-to-severe CKD-associated pruritus in adult patients who are undergoing haemodialysis. This will allow patients in Northern Ireland, England, and Wales to get

The regulatory agency has determined that the NDA is a class 2 review, which leads to a six-month review period from the date of resubmission. It has set

OCA is a farnesoid X receptor (FXR) agonist, which is marketed as Ocaliva by Intercept in the US to treat PBC. Bezafibrate is a pan-peroxisome proliferator-activated receptor (pan-PPAR)